Cure My Disease

Don't miss your cure!

 Log in / Sign up

Personalized brain zaps show promise for autism language delays

NCT ID NCT07515261

Symptom relief Sponsor: Changping Laboratory Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This small pilot study tested whether a non-invasive brain stimulation technique called TMS, guided by each person's unique brain map, could help improve language and social skills in 22 children and young adults with autism and language delay. The treatment targeted a specific brain area involved in social and emotional functions. Researchers measured changes in vocabulary and social behavior to see if the approach was feasible and worth studying further.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

22 people

The number who actually took part.

Started

Mar 2023

Finished

May 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 30 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 6-30 years old * Have the diagnosis of autism spectrum disorder * ADOS-2 score is higher than the ASD cut-offs * Have language development delay (the WISC-4 Verbal Comprehension Index lower than 70) * Capacity to follow the study procedures, including fMRI scan under sedation, assessment, and rehabilitation training * Participant's parents or other legal guardians give informed consent Exclusion Criteria: * Current or history of psychotic disorders, such as schizophrenia, schizoaffective disorder, bipolar disorder * Severe self-injury or suicidal behavior presented in the last 1 year * Severe visual, auditory, or motor disability that interferes with any study procedure * Current, history or family history of epilepsy * Known severe physical diseases, such as congenital heart defect, traumatic brain injury * Metal implantations, which are contradicted by MRI or TMS, such as artificial cardiac pacemakers, stents, cochlear implants * Received TMS, tCS, FUS, or other neuromodulation treatment in the last 3 months * Currently participating in other clinical trials

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autism spectrum disorder with language delay are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autism spectrum disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autism spectrum disorder with language delay

Contacts and locations

Locations

  • China Rehabilitation Research Center

    Beijing, China